HC Wainwright & Co. Reiterates Buy on Calliditas Therapeutics, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edwin Zhang has reiterated a 'Buy' rating on Calliditas Therapeutics (NASDAQ:CALT) and maintained a $50 price target.
October 16, 2023 | 4:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calliditas Therapeutics (NASDAQ:CALT) has had its 'Buy' rating reiterated by HC Wainwright & Co. with a maintained price target of $50.
The reiteration of a 'Buy' rating and a maintained price target of $50 by HC Wainwright & Co. is a positive signal for Calliditas Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100